• 1. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 2. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 3. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726
• 4. Evolutionary approaches in protein engineering towards biomaterial construction
  Brindha J.,Balamurali M. M.,Kaushik Chanda RSC Adv., 2019,9, 34720-34734
• 5. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Biphenyls and derivatives Chlorinated biphenyls

Recent Advances in the Study of 2'-Chloro-[1,1'-Biphenyl]-3-Carbaldehyde (CAS: 675596-30-2) in Chemical Biology and Pharmaceutical Research

2'-Chloro-[1,1'-biphenyl]-3-carbaldehyde (CAS: 675596-30-2) is a key intermediate in the synthesis of various bioactive compounds, particularly in the development of pharmaceuticals targeting inflammatory and oncological diseases. Recent studies have highlighted its role as a versatile building block in medicinal chemistry, enabling the construction of complex molecular architectures with enhanced pharmacological properties. This research brief consolidates the latest findings on this compound, focusing on its synthetic applications, biological activities, and potential therapeutic implications.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 2'-chloro-[1,1'-biphenyl]-3-carbaldehyde in the synthesis of novel kinase inhibitors. The research team utilized this compound as a pivotal intermediate to develop a series of derivatives exhibiting potent inhibitory activity against JAK2 and FLT3 kinases, which are critical targets in myeloproliferative disorders. The study reported IC50 values in the nanomolar range, suggesting high specificity and potential for further clinical development.

In the field of anti-inflammatory drug discovery, a recent patent application (WO2023056789) disclosed the use of 675596-30-2 in the preparation of biphenyl-based COX-2 selective inhibitors. The structural flexibility offered by the chloro and aldehyde functional groups allowed for precise modulation of the compounds' selectivity profiles, yielding candidates with improved gastrointestinal safety compared to traditional NSAIDs. Molecular docking studies revealed that these derivatives occupy a unique binding pocket in the COX-2 active site, explaining their enhanced selectivity.

Advanced synthetic methodologies have been developed to optimize the production of 2'-chloro-[1,1'-biphenyl]-3-carbaldehyde. A 2024 publication in Organic Process Research & Development described a continuous flow chemistry approach that improved the yield to 92% while reducing hazardous waste generation by 65% compared to traditional batch processes. This green chemistry innovation addresses both economic and environmental concerns in large-scale pharmaceutical manufacturing.

Emerging research has also explored the compound's potential in targeted drug delivery systems. Scientists have functionalized the aldehyde group of 675596-30-2 to create pH-responsive prodrugs that release active pharmaceutical ingredients specifically in tumor microenvironments. Preliminary in vivo studies in xenograft models showed a 40% increase in tumor accumulation compared to non-targeted controls, with corresponding reductions in systemic toxicity.

Quality control and analytical characterization of 2'-chloro-[1,1'-biphenyl]-3-carbaldehyde have seen significant advancements. Recent developments in HPLC-MS methods now allow for detection of impurities at the 0.1% level, ensuring compliance with stringent regulatory requirements for pharmaceutical intermediates. These analytical improvements are crucial for maintaining batch-to-batch consistency in industrial applications.

In conclusion, 2'-chloro-[1,1'-biphenyl]-3-carbaldehyde continues to demonstrate significant value in pharmaceutical research and development. Its versatile chemical properties enable diverse therapeutic applications, while recent synthetic and analytical advancements have improved its accessibility and quality. Ongoing research is expected to further expand its utility in drug discovery programs, particularly in the areas of precision medicine and targeted therapies.

• 79213-60-8(2-chloro-4-phenylbenzaldehyde)
• 1261478-27-6(2,2',4',5'-Tetrachlorobiphenyl-4-carboxaldehyde)
• 885963-22-4([1,1'-Biphenyl]-3-carboxaldehyde,3'-chloro-4'-methyl-)
• 885964-20-5(4'-fluoro-3'-methyl-[1,1'-biphenyl]-4-carbaldehyde)
• 885963-06-4([1,1'-Biphenyl]-4-carboxaldehyde,3'-chloro-4'-methyl-)
• 39802-78-3(2'-Chloro1,1'-biphenyl-4-carbaldehyde)
• 1361555-00-1(6,2',3',5'-Tetrachlorobiphenyl-3-carboxaldehyde)
• 142068-75-5([1,1':4',1'':4'',1'''-Quaterphenyl]-4,4'''-dicarboxaldehyde, 2',3''-dichloro-)
• 142068-82-4([1,1'-BIPHENYL]-4,4'-DICARBOXALDEHYDE, 2-CHLORO-)
• 57592-44-6(3-Chloro-4-phenylbenzaldehyde)